Neuroendocrine tumors of the prostate.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29297494.
- Also identified by DOI 10.1038/modpathol.2017.164.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neuroendocrine (NE) differentiation in tumors of the prostate or in the setting of prostate cancer (PCa) is rare. A survey of these lesions is presented, including usual PCa with focal NE marker-positive cells, Paneth cell-like change, prostatic 'carcinoid', high-grade NE carcinoma, as well as other tumors that do not fit neatly into these categories. The most significant clinical and pathologic features, emerging molecular evidence and the importance of differentiating NE tumors involving the prostate from secondary involvement are highlighted.
Medical subject headings
- Adenocarcinoma
- Adenocarcinoma/pathology
- Biomarkers, Tumor
- Carcinoid Tumor
- Carcinoid Tumor/pathology
- Carcinoma, Neuroendocrine
- Carcinoma, Neuroendocrine/pathology
- Humans
- Immunohistochemistry
- Male
- Neuroendocrine Cells
- Neuroendocrine Cells/pathology
- Neuroendocrine Tumors
- Neuroendocrine Tumors/classification
- Neuroendocrine Tumors/pathology
- Prostate
- Prostate/pathology
- Prostatic Neoplasms
- Prostatic Neoplasms/classification
- Prostatic Neoplasms/pathology